Yes. Treatment of venous thromboembolism (VTE) or atrial fibrillation in patients with
elevated BMIs with a direct oral anticoagulant (DOAC) appears to be equivalent to warfarin …

Introduction Current guidelines and consensus statements have advised against the use of
direct oral anticoagulants (DOACs) for morbidly obese patients (BMI> 40 kg/m2), indicating …

Introduction: The safety and efficacy of direct oral anticoagulants (DOACs) compared to
vitamin K antagonists (VKAs) remain unknown in patients with BMI≥ 40 kg/m2. We aim to …

Background: While commonly prescribed today, direct oral anticoagulants (DOACs) have
historically been avoided in patients with class III obesity or a weight> 120 kg due to limited …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

The effectiveness and safety of direct oral anticoagulants (DOAC) compared with warfarin
remains uncertain in obese patients. We assessed the comparative effectiveness and safety …

Methods We systematically searched databases from their inception to October 3, 2023, to
review and examine the effectiveness and safety of DOACs compared to warfarin in patients …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Dear editor, There has always been unresolved uncertainty regarding the therapeutic utility
of direct oral anticoagulants (DOACs) in morbidly obese patients (BMI> 40 kg/m2 or weight> …